Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Increased Risk of Heart Attack / Stroke in Users of Long-Acting Inhaled Bronchodilators

January 3, 2018 By Law Offices of Thomas J. Lamb, P.A.


Types of Long-Acting Inhaled Bronchodilators

Long-acting inhaled bronchodilators — such as long-acting beta-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) — are used to treat patients with chronic obstructive pulmonary disease (COPD).  They function by expanding the airways and helping them stay expanded for a longer period of time.

Rather than a short-term inhaler, these medicines are meant to be used on a long-term basis for the maintenance treatment of COPD.  Many are prescribed twice daily to prevent COPD symptoms such as wheezing, coughing, chest tightness, and shortness of breath.

LABAs available in the United States include:

  • Brovana (arformoterol)
  • Perforomist (formoterol)
  • Foradil (formoterol)
  • Arcapta (indacaterol)
  • Serevent Diskus (salmeterol)
  • Striverdi Respimat (olodaterol)

LAMAs available in the United States include:

  • Spiriva (tiotropium)
  • Seebri (glycopyrronium bromide)
  • Incruse Ellipta (umeclidinium)

Some of these medicines — such as Arcapta and Serevent Diskus — are also indicated in the treatment of asthma.

 

New Increased Cardiovascular Risks

A recent study involving over 280,000 patients with COPD suggests that users of LABAs and LAMAs have an increased risk of heart attacks and strokes within the first several weeks of using these medicines.

More specifically, patients who used these medicines experienced a 50% increased risk of a severe cardiovascular event within the first 30 days of use.  After that time period, however, the risk declined.

Here is an excerpt from the “Conclusions and Relevance” section of the study’s Abstract:

New initiation of LABAs or LAMAs in patients with COPD is associated with an approximate 1.5-fold increased severe cardiovascular risk, irrespective of prior CVD status and history of exacerbations.

These medicines can put their users at risk of serious cardiovascular events because they:

  • accelerate the heart rate;
  • construct the blood vessels;
  • increase blood pressure; and,
  • may also increase inflammation.

 

Possible Product Label Change

Though he was not part of the study, Dr. Tadahiro Goto, a researcher at Massachusetts General Hospital in Boston, provided the following commentary (excerpted from a recent Reuters article):

Patients should know that their risk for cardiovascular diseases will be increased after initiation of bronchodilators even though the treatment is essential.  While patients shouldn’t stop using inhalers, they should be vigilant about seeking medical attention for symptoms that might indicate a heart problem, such as chest pains or a suddenly rapid heart beat.

It is true that patients should be aware of the risks involved with using these medicines.  Going forward, it will be interesting to see whether the FDA and other regulatory bodies agree, and mandate that the risk of heart attacks and strokes be added to the product labels for these medicines.

We will continue to monitor the medical and regulatory literature concerning the risk of cardiovascular events due to LABAs and LAMAs, and report on significant events.

 

Written by: Heather Helmendach, Legal Assistant 
Law Offices of Thomas J. Lamb, P.A.

 

Drug Injury Watch: Side Effects News & Reports

Drug Injury Law: Medical & Legal Information

Filed Under: Unsafe Drugs Tagged With: cardiovascular events, chronic obstructive pulmonary disease, COPD treatment side effects, Heart Attack, LABAs, LAMAs, long-acting beta-agonists, Long-acting inhaled bronchodilators, long-acting muscarinic antagonists, Stroke

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.